Cargando…
A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study( )
BACKGROUND: Both the elderly and individuals with comorbidities are at increased risk of developing influenza-related complications. Novel influenza antivirals are required, given limitations of current drugs (eg, resistance emergence and poor efficacy). Pimodivir is a first-in-class antiviral for i...
Autores principales: | O’Neil, Brian, Ison, Michael G, Hallouin-Bernard, Marie Charlotte, Nilsson, Anna C, Torres, Antoni, Wilburn, John M, van Duijnhoven, Wilbert, Van Dromme, Ilse, Anderson, David, Deleu, Sofie, Kosoglou, Teddy, Vingerhoets, Johan, Rossenu, Stefaan, Leopold, Lorant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373154/ https://www.ncbi.nlm.nih.gov/pubmed/32604406 http://dx.doi.org/10.1093/infdis/jiaa376 |
Ejemplares similares
-
Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir
por: Patel, Mira C., et al.
Publicado: (2021) -
Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir
por: Soh, Y. Q. Shirleen, et al.
Publicado: (2021) -
1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005
por: Martinon-Torres, Federico, et al.
Publicado: (2018) -
Impact of Health Insurance Expansions on Nonelderly Adults With Hypertension
por: Li, Suhui, et al.
Publicado: (2015) -
Prescription Drug Use Among Elderly and Nonelderly Families
por: McKercher, Patrick L., et al.
Publicado: (2003)